HRP20160082T1 - Sastavi i postupci za dijagnosticiranje i lijeäśenje raka - Google Patents
Sastavi i postupci za dijagnosticiranje i lijeäśenje raka Download PDFInfo
- Publication number
- HRP20160082T1 HRP20160082T1 HRP20160082TT HRP20160082T HRP20160082T1 HR P20160082 T1 HRP20160082 T1 HR P20160082T1 HR P20160082T T HRP20160082T T HR P20160082TT HR P20160082 T HRP20160082 T HR P20160082T HR P20160082 T1 HRP20160082 T1 HR P20160082T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antibody
- variable region
- antibody according
- amino acid
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 201000011510 cancer Diseases 0.000 title claims 4
- 239000000203 mixture Substances 0.000 title 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 4
- 239000013612 plasmid Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000044457 human DLL4 Human genes 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (13)
1. Protutijelo koje se specifično veže na humani DLL4, naznačeno time, da je sljedeće:
(a) protutijelo 21 M18 H7L2 kodirano putem plazmida koji je deponiran pod ATCC pristupnim brojem PTA-8425;
(b) protutijelo 21 M18 H9L2 kodirano putem plazmida koji je deponiran pod ATCC pristupnim brojem PTA-8427; ili
(c) monoklonalno protutijelo koje obuhvaća:
varijabilno područje jakog lanca koje sadrži CDR aminokiselinske sekvence CDR1, CDR2 i CDR3, pri čemu
CDR1 je SEQ ID NO:1;
CDR2 je SEQ ID NO:3, SEQ ID NO:2 ili SEQ ID NO:4; i
CDR3 je SEQ ID NO:5; i
varijabilno područje slabog lanca koje sadrži CDR aminokiselinske sekvence CDR1, CDR2 i CDR3, pri čemu
CDR1 je SEQ ID NO:9;
CDR2 je SEQ ID NO:10; i
CDR3 je SEQ ID NO:11.
2. Protutijelo prema zahtjevu 1 (c), naznačeno time, da je CDR2 jakog lanca je SEQ ID NO:3.
3. Protutijelo prema zahtjevu 2, naznačeno time, da protutijelo obuhvaća sljedeće:
(a) varijabilno područje jakog lanca koje ima najmanje 90% identiteta sekvence od SEQ ID NO:7, i
(b) varijabilno područje slabog lanca koje ima najmanje 90% identiteta sekvence od SEQ ID NO:12.
4. Protutijelo prema zahtjevu 1 (c), naznačeno time, da aminokiselinska sekvenca varijabilnog područja jakog lanca je SEQ ID NO:7, SEQ ID NO:6 ili SEQ ID NO:8, i
aminokiselinska sekvenca varijabilnog područja slabog lanca je SEQ ID NO:12.
5. Protutijelo prema zahtjevu 4, naznačeno time, da ono obuhvaća varijabilno područje jakog lanca aminokiselinske sekvence SEQ ID NO:7, i
varijabilno područje slabog lanca aminokiselinske sekvence SEQ ID NO:12.
6. Protutijelo prema bilo kojem od zahtjeva 1 (c) do 5, naznačeno time, da protutijelo je humanizirano protutijelo.
7. Izolirani polinukleotid, naznačen time, da kodira polipeptid koji obuhvaća protutijelo prema bilo kojem od zahtjeva 1 do 6.
8. Izolirani polinukleotid, naznačen time, da je on plazmid deponiran pod ATCC pristupnim brojem PTA-8425 ili pod ATCC pristupnim brojem PTA-8427.
9. Hibridom, naznačen time, da on izlučuje protutijelo 21 M18 deponirano kod ATCC dana 28. rujna 2007. godine i koje ima ATCC pristupni broj PTA-8670.
10. Farmaceutski sastav, naznačen time, da obuhvaća sljedeće:
protutijelo prema bilo kojem od zahtjeva 1 do 6; i
farmaceutski prihvatljiv nosač.
11. Protutijelo prema bilo kojem od zahtjeva 1 do 6, naznačeno time, da se upotrebljava u liječenju raka.
12. Protutijelo za uporabu prema zahtjevu 11, naznačeno time, da liječenje raka obuhvaća primjenu protutijela i drugog terapeutskog sredstva.
13. Uporaba protutijela prema bilo kojem od zahtjeva 1 do 6, naznačena time, da je za proizvodnju lijeka za liječenje raka.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84790406P | 2006-09-29 | 2006-09-29 | |
US88626007P | 2007-01-23 | 2007-01-23 | |
US94254207P | 2007-06-07 | 2007-06-07 | |
PCT/US2007/020889 WO2008042236A2 (en) | 2006-09-29 | 2007-09-28 | Compositions and methods for diagnosing and treating cancer |
EP07838966.5A EP2066694B1 (en) | 2006-09-29 | 2007-09-28 | Compositions and methods for diagnosing and treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20160082T1 true HRP20160082T1 (hr) | 2016-02-26 |
Family
ID=39268983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20160082TT HRP20160082T1 (hr) | 2006-09-29 | 2016-01-26 | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka |
Country Status (28)
Country | Link |
---|---|
US (5) | US7750124B2 (hr) |
EP (3) | EP2562188A3 (hr) |
JP (3) | JP5535633B2 (hr) |
KR (1) | KR101477824B1 (hr) |
AU (1) | AU2007305443B2 (hr) |
BR (1) | BRPI0717431A2 (hr) |
CA (1) | CA2664738C (hr) |
CO (1) | CO6180466A2 (hr) |
CR (1) | CR10667A (hr) |
CY (1) | CY1117154T1 (hr) |
DK (1) | DK2066694T3 (hr) |
EA (1) | EA018260B1 (hr) |
ES (1) | ES2557953T3 (hr) |
HK (1) | HK1133268A1 (hr) |
HR (1) | HRP20160082T1 (hr) |
HU (1) | HUE028379T2 (hr) |
IL (1) | IL197721A (hr) |
MA (1) | MA30808B1 (hr) |
ME (1) | ME02371B (hr) |
MX (1) | MX2009003229A (hr) |
NO (1) | NO20091635L (hr) |
NZ (1) | NZ576404A (hr) |
PL (1) | PL2066694T3 (hr) |
PT (1) | PT2066694E (hr) |
RS (1) | RS54452B1 (hr) |
SI (1) | SI2066694T1 (hr) |
WO (1) | WO2008042236A2 (hr) |
ZA (1) | ZA200901615B (hr) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7906116B2 (en) * | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
US7919092B2 (en) | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
MX2009003229A (es) * | 2006-09-29 | 2009-06-18 | Oncomed Pharm Inc | Composiciones y metodos para diagnosticar y tratar cancer. |
NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
AU2008209482B2 (en) * | 2007-01-24 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
WO2008091222A1 (en) * | 2007-01-26 | 2008-07-31 | Bioinvent International Ab | Dll4 signaling inhibitors and uses thereof |
GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
AU2008270972B2 (en) | 2007-07-02 | 2013-10-24 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
US8119366B2 (en) | 2007-10-05 | 2012-02-21 | Trojan Technologies, Ltd. | Antennapedia-dominant negative mastermind-like construct |
BRPI0910482A2 (pt) | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
US8034337B2 (en) * | 2008-05-30 | 2011-10-11 | Xbiotech, Inc. | Interleukin-1α antibodies |
JP5723769B2 (ja) | 2008-06-03 | 2015-05-27 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
JP2011523853A (ja) | 2008-06-03 | 2011-08-25 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリン及びその使用 |
PT2307051E (pt) | 2008-07-08 | 2015-05-21 | Oncomed Pharm Inc | Antagonistas e agentes de ligação a notch e métodos de utilização dos mesmos |
BRPI0915448A2 (pt) | 2008-07-08 | 2015-11-10 | Abbott Lab | imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas |
US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
US8652843B2 (en) | 2008-08-12 | 2014-02-18 | Oncomed Pharmaceuticals, Inc. | DDR1-binding agents and methods of use thereof |
US8192738B2 (en) * | 2008-09-19 | 2012-06-05 | Medimmune, Llc | Targeted antibodies directed to DLL4 |
JP5882058B2 (ja) * | 2008-11-07 | 2016-03-09 | ファブラス エルエルシー | 組合せ抗体ライブラリー及びその使用 |
LT2842573T (lt) | 2008-11-07 | 2017-12-11 | Galaxy Biotech, Llc | Monokloniniai antikūnai prieš fibroblastų augimo faktoriaus receptorių-2 |
CA2759233C (en) | 2009-04-27 | 2019-07-16 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以dll4拮抗劑與化學治療劑治療癌症之方法 |
PE20121647A1 (es) * | 2009-08-29 | 2012-12-31 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
AU2010289527C1 (en) | 2009-09-01 | 2014-10-30 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
JP2013507928A (ja) | 2009-10-15 | 2013-03-07 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
PT2488204E (pt) | 2009-10-16 | 2016-06-09 | Oncomed Pharm Inc | Combinação terapêutica e utilização de anticorpos antagonistas de dll4 e agentes anti-hipertensivos |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
US8945569B2 (en) | 2009-11-19 | 2015-02-03 | Oncomed Pharmaceuticals, Inc. | Jagged-binding agents and uses thereof |
JP2013512278A (ja) * | 2009-12-01 | 2013-04-11 | オンコメッド ファーマシューティカルズ インコーポレイテッド | K−ras変異を含んだ癌を処置するための方法 |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
AU2011205316B2 (en) | 2010-01-13 | 2015-05-28 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
JP5808349B2 (ja) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | セラノーシスのためのバイオマーカー |
JP5964249B2 (ja) * | 2010-03-02 | 2016-08-03 | アッヴィ・インコーポレイテッド | 治療用dll4結合タンパク質 |
KR20130043104A (ko) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
CN103298834A (zh) | 2010-08-03 | 2013-09-11 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
EP2606353A4 (en) * | 2010-08-18 | 2014-10-15 | Caris Life Sciences Luxembourg Holdings | CIRCULATING BIOMARKERS FOR DISEASE |
AU2011293253B2 (en) | 2010-08-26 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
WO2012068098A1 (en) * | 2010-11-15 | 2012-05-24 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with dll4 antagonists |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
JP2014515821A (ja) | 2011-03-27 | 2014-07-03 | オンコステム ダイアグノスティックス(モーリシャス)プライベート リミテッド | 腫瘍細胞を同定するためのマーカー、その方法およびキット |
CA2838973A1 (en) * | 2011-06-17 | 2012-12-20 | Adrian L. Harris | Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies |
CN106167526A (zh) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | Rspo结合剂和其应用 |
US20130108641A1 (en) * | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
WO2013044215A1 (en) * | 2011-09-23 | 2013-03-28 | Oncomed Pharmaceuticals, Inc. | Vegf/dll4 binding agents and uses thereof |
JP2015508994A (ja) | 2011-12-30 | 2015-03-26 | アッヴィ・インコーポレイテッド | Il−13および/またはil−17に対する二重可変ドメイン免疫グロブリン |
JP2015520172A (ja) * | 2012-05-31 | 2015-07-16 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | Dll−4に結合する抗原結合蛋白質 |
US20140056890A1 (en) | 2012-06-06 | 2014-02-27 | Oncomed Pharmaceuticals, Inc. | Binding Agents That Modulate the Hippo Pathway and Uses Thereof |
US9181333B2 (en) | 2012-07-13 | 2015-11-10 | Oncomed Pharmaceuticals, Inc. | RSPO3 binding agents and uses thereof |
DK2888283T3 (en) | 2012-08-24 | 2018-11-19 | Univ California | ANTIBODIES AND VACCINES FOR TREATING ROR1 CANCER AND INHIBITIVE METASTASE |
EP2906295A4 (en) * | 2012-10-15 | 2016-06-01 | Oncomed Pharm Inc | METHODS OF TREATING OCULAR DISEASES |
WO2014071018A1 (en) * | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
BR112015009961B1 (pt) | 2012-11-01 | 2020-10-20 | Abbvie Inc. | proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende |
TW201438736A (zh) | 2012-11-14 | 2014-10-16 | Regeneron Pharma | 以dll4拮抗劑治療卵巢癌之方法 |
CN104902913A (zh) | 2012-12-04 | 2015-09-09 | 昂科梅德制药有限公司 | 使用结合剂的免疫治疗 |
JP6449537B2 (ja) * | 2012-12-27 | 2019-01-09 | 日本メジフィジックス株式会社 | 抗腫瘍剤、及び、抗腫瘍用キット |
US9062108B2 (en) | 2013-03-15 | 2015-06-23 | Abbvie Inc. | Dual specific binding proteins directed against IL-1 and/or IL-17 |
GB201312727D0 (en) * | 2013-07-16 | 2013-08-28 | Isis Innovation | Modulators |
LT3027651T (lt) | 2013-08-01 | 2019-04-10 | Five Prime Therapeutics, Inc. | Afukozilinti anti-fgfr2iiib antikūnai |
CN105829547A (zh) | 2013-12-02 | 2016-08-03 | 昂科梅德制药有限公司 | 与Wnt途径抑制剂有关的预测性生物标记物的鉴别 |
US10214584B2 (en) | 2014-01-15 | 2019-02-26 | Order-Made Medical Research Inc. | Therapeutic pharmaceutical composition employing anti-SLC6A6 antibody |
RS59789B1 (sr) * | 2014-07-21 | 2020-02-28 | Delinia Inc | Molekuli koji selektivno aktiviraju regulatorne t ćelije u tretmanima autoimunih bolesti |
AU2015317986A1 (en) | 2014-09-16 | 2017-03-09 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
EP3212233B1 (en) * | 2014-10-31 | 2020-06-24 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
AU2016359609B2 (en) | 2015-11-23 | 2023-12-07 | Five Prime Therapeutics, Inc. | FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
JP7035026B2 (ja) | 2016-05-19 | 2022-03-14 | サンタ アナ テック エルエルシー | 加熱された切除ゾーンを生成し組織に適用するためのダブルバルーン構造を有するカテーテル |
WO2017205651A1 (en) * | 2016-05-25 | 2017-11-30 | The Trustees Of Columbia University In The City Of New York | Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling |
JP7109007B2 (ja) | 2016-06-27 | 2022-07-29 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | がん治療の組み合わせ |
JP2019528077A (ja) | 2016-08-23 | 2019-10-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法 |
EP3515491A4 (en) * | 2016-09-21 | 2020-09-16 | Aptevo Research and Development LLC | CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCEDURES |
EP3538548A4 (en) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
RU2765410C2 (ru) | 2016-11-30 | 2022-01-28 | Онкомед Фармасьютикалс, Инк. | Способы лечения рака, включающие связывающие tigit агенты |
JP7299842B2 (ja) | 2017-05-16 | 2023-06-28 | ファイヴ プライム セラピューティクス インク | がん治療における化学療法剤と組み合わせた抗fgfr2抗体 |
AU2019338398A1 (en) | 2018-09-11 | 2021-05-20 | Aqua Heart, Inc. | Heated vapor ablation systems and methods for treating cardiac conditions |
WO2020102644A2 (en) | 2018-11-15 | 2020-05-22 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with vegf/dll4 binding agent |
WO2021041818A1 (en) | 2019-08-28 | 2021-03-04 | Santa Anna Tech Llc | Systems and methods for ablating prostate tissue |
WO2023149977A1 (en) * | 2022-02-04 | 2023-08-10 | Mereo Biopharma 5, Inc. | Methods for treating cancer |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
FR2248608B1 (hr) * | 1973-10-17 | 1977-05-27 | Labo Electronique Physique | |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
IL101728A (en) | 1991-05-03 | 2007-08-19 | Univ Yale | Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them |
US20050112121A1 (en) | 1992-04-30 | 2005-05-26 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US5786158A (en) | 1992-04-30 | 1998-07-28 | Yale University | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids |
US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6262025B1 (en) | 1995-06-28 | 2001-07-17 | Imperial Cancer Research Technology, Ltd. | Nucleotide and protein sequences of vertebrate delta genes and methods based thereon |
US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
JPH09124697A (ja) | 1995-11-01 | 1997-05-13 | Toagosei Co Ltd | ペプチド及びモノクローナル抗体 |
US6337387B1 (en) | 1995-11-17 | 2002-01-08 | Asahi Kasei Kabushiki Kaisha | Differentiation-suppressive polypeptide |
US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20060122373A1 (en) | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
US6121045A (en) | 1997-04-04 | 2000-09-19 | Millennium Biotherapeutics, Inc. | Human Delta3 nucleic acid molecules |
US20030180784A1 (en) | 1997-04-04 | 2003-09-25 | Millennium Pharmaceuticals, Inc. | Novel human Delta3 compositions and therapeutic and diagnostic uses therefor |
ATE342358T1 (de) | 1997-04-04 | 2006-11-15 | Millennium Biotherapeutics Inc | Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
DE122005000026I1 (de) | 1997-04-07 | 2005-08-04 | Genentech Inc | Anti-VEGF Antik¦rper. |
US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
JP2001527403A (ja) | 1997-04-25 | 2001-12-25 | ジェネティックス・インスチチュート・インコーポレーテッド | 分泌蛋白およびそれらをコードするポリヌクレオチド |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック,インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
WO1998051799A1 (fr) | 1997-05-14 | 1998-11-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Nouvel inhibiteur de differentiation |
AU8162898A (en) | 1997-06-18 | 1999-01-04 | Trustees Of Columbia University In The City Of New York, The | Angiogenic modulation by notch signal transduction |
US6004528A (en) | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
EP1100899A2 (en) | 1998-07-27 | 2001-05-23 | Amgen Inc. | Delta-related polypeptides |
US6887468B1 (en) | 1999-04-28 | 2005-05-03 | Board Of Regents, The University Of Texas System | Antibody kits for selectively inhibiting VEGF |
RS50073B (sr) | 1999-06-08 | 2009-01-22 | Regeneron Pharmaceuticals I.N.C., | Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama |
WO2001007611A2 (en) | 1999-07-26 | 2001-02-01 | Genentech, Inc. | Novel polynucleotides and method for the use thereof |
CA2391455A1 (en) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1268543A2 (en) | 2000-04-05 | 2003-01-02 | Kirin Beer Kabushiki Kaisha | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
US20110131679A2 (en) | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
GB0014185D0 (en) * | 2000-06-09 | 2000-08-02 | Novartis Res Found | Compound and method |
US20020028488A1 (en) * | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
WO2003050502A2 (en) | 2001-12-07 | 2003-06-19 | Regents Of The University Of Michigan | Prospective identification and characterization of breast cancer stem cells |
US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
US6689744B2 (en) | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
US7667004B2 (en) | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
EP1410018A1 (en) | 2001-07-25 | 2004-04-21 | Lorantis Limited | Method for detecting modultators of notch signalling |
WO2003012105A2 (en) | 2001-08-01 | 2003-02-13 | University Of Bristol | Vegf isoform |
US20050137130A1 (en) | 2001-11-14 | 2005-06-23 | Bodmer Mark W. | Medical treatment |
JP2005518785A (ja) * | 2001-11-14 | 2005-06-30 | ロランティス リミテッド | 内科療法 |
AU2002339157A1 (en) | 2001-11-14 | 2003-05-26 | Lorantis Limited | Inhibitors of the notch signalling pathway for use in the treatment of cancer |
US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
GB0218879D0 (en) | 2002-08-14 | 2002-09-25 | Lorantis Ltd | Medical treatment |
JP2006515177A (ja) | 2002-09-10 | 2006-05-25 | ロランティス リミテッド | Notchリガンドタンパク質を含む医薬組成物及び医学的処置 |
US7354578B2 (en) | 2003-06-06 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with VEGF inhibitors |
US7758859B2 (en) | 2003-08-01 | 2010-07-20 | Genentech, Inc. | Anti-VEGF antibodies |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US20050079184A1 (en) | 2003-08-08 | 2005-04-14 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
FR2859725B1 (fr) | 2003-09-16 | 2006-03-10 | Neovacs | Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine |
JP2008502738A (ja) | 2004-06-10 | 2008-01-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトの癌を処置するための、vegfインヒビターの使用 |
US20050281822A1 (en) | 2004-06-18 | 2005-12-22 | Cedarbaum Jesse M | Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion |
AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
WO2006027693A2 (en) | 2004-09-09 | 2006-03-16 | Exonhit Therapeutics Sa | Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis |
CA2580981C (en) | 2004-09-22 | 2013-10-22 | Kirin Beer Kabushiki Kaisha | Stabilized human igg4 antibodies |
US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
BRPI0517564A (pt) | 2004-11-10 | 2008-10-14 | Hubrecht Lab | métodos para modificar o destino de uma célula de adenoma e/ou adenocarcinoma, para induzir a formação de uma célula pós-mitótica a partir de um célula de adenoma e/ou adenocarcinoma e para, pelo menos em parte, diminuir um adenoma e/ou adenocarcinoma intestinal presente em um animal, uso de um inibidor do trajeto de notch, e, composição farmacêutica |
EP1812064A4 (en) | 2004-11-19 | 2009-07-08 | Cornell Res Foundation Inc | USE OF ENDOTHELIAL VASCULAR GROWTH FACTOR RECEPTOR CELLS IN THE TREATMENT AND MONITORING OF CANCER AND IN THE SCREENING OF CHEMOTHERAPEUTIC AGENTS |
US7432107B2 (en) | 2005-01-24 | 2008-10-07 | Roche Diagnostics Operations, Inc. | Cardiac hormones for assessing cardiovascular risk |
JP2008537538A (ja) | 2005-02-11 | 2008-09-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Vegf拮抗剤及び降圧剤の治療的組み合わせ |
EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
US9296816B2 (en) | 2005-04-15 | 2016-03-29 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
JP2008545753A (ja) | 2005-06-02 | 2008-12-18 | ギャラクシー バイオテック, エルエルシー | 抗体で脳腫瘍を処置する方法 |
MX2008001966A (es) | 2005-08-12 | 2008-03-26 | Regeneron Pharma | Tratamiento de enfermedades mediante administracion subcutanea de un antagonista vegf. |
US7906116B2 (en) | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
AU2006287228B2 (en) | 2005-09-01 | 2012-12-13 | Alora Biopharma, Inc. | Methods for using and identifying modulators of Delta-like 4 |
PL1962895T3 (pl) * | 2005-12-16 | 2013-06-28 | Regeneron Pharma | Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów |
EP1993541A2 (en) | 2006-02-17 | 2008-11-26 | Gilead Colorado, Inc. | Antihypertensive therapy |
US7354582B2 (en) | 2006-03-10 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Use of VEGF antagonists for the treatment of malignant gliomas |
CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
JP2009539384A (ja) * | 2006-06-06 | 2009-11-19 | ジェネンテック・インコーポレーテッド | 抗dll4抗体および抗dll4抗体使用の方法 |
WO2007143689A2 (en) | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions and methods for modulating vascular development |
US7919092B2 (en) * | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
UA95304C2 (ru) | 2006-08-07 | 2011-07-25 | Ридженерон Фармасьютикалз, Инк. | Применение антагониста dll4 для предотвращения или снижения потери кровеносных сосудов |
WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
MX2009003229A (es) | 2006-09-29 | 2009-06-18 | Oncomed Pharm Inc | Composiciones y metodos para diagnosticar y tratar cancer. |
WO2008133706A2 (en) | 2006-10-20 | 2008-11-06 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
US20100166746A1 (en) | 2006-12-04 | 2010-07-01 | Medlmmune Way | High potency recombinant antibodies, methods for producing them and use in cancer therapy |
EP2099489B1 (en) | 2006-12-11 | 2014-05-21 | Genentech, Inc. | Compositions and methods for treating a neoplasm |
NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
WO2008077077A2 (en) | 2006-12-19 | 2008-06-26 | Genentech, Inc. | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
AU2007338734A1 (en) | 2006-12-20 | 2008-07-03 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
WO2008091222A1 (en) * | 2007-01-26 | 2008-07-31 | Bioinvent International Ab | Dll4 signaling inhibitors and uses thereof |
US20120040025A9 (en) | 2007-05-04 | 2012-02-16 | Currie Mark G | Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention |
GB0709333D0 (en) | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
US8216571B2 (en) | 2007-10-22 | 2012-07-10 | Schering Corporation | Fully human anti-VEGF antibodies and methods of using |
WO2009053987A1 (en) | 2007-10-25 | 2009-04-30 | University Of Bristol | Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf) |
WO2009075565A1 (en) | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Methods for controlling vasculogenesis |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
BRPI0910482A2 (pt) | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
JP5882058B2 (ja) | 2008-11-07 | 2016-03-09 | ファブラス エルエルシー | 組合せ抗体ライブラリー及びその使用 |
AR074726A1 (es) | 2008-12-12 | 2011-02-09 | Boehringer Ingelheim Int | Anticuerpos anti-igf (factor de crecimiento insulinico) |
WO2010123891A1 (en) | 2009-04-20 | 2010-10-28 | Genentech, Inc. | Adjuvant cancer therapy |
WO2010124009A2 (en) | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
CA2759233C (en) | 2009-04-27 | 2019-07-16 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
AU2010270844A1 (en) | 2009-07-08 | 2011-12-22 | Amgen Inc. | Design of stable and aggregation free antibody Fc molecules through CH3 domain interface engineering |
US20110172398A1 (en) | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
PT2488204E (pt) | 2009-10-16 | 2016-06-09 | Oncomed Pharm Inc | Combinação terapêutica e utilização de anticorpos antagonistas de dll4 e agentes anti-hipertensivos |
CN102686609A (zh) | 2009-10-23 | 2012-09-19 | 加文医学研究所 | 修饰的可变域分子及其生产和使用方法 |
JP2013512278A (ja) | 2009-12-01 | 2013-04-11 | オンコメッド ファーマシューティカルズ インコーポレイテッド | K−ras変異を含んだ癌を処置するための方法 |
AU2011215685B2 (en) | 2010-02-12 | 2015-08-20 | Oncomed Pharmaceuticals, Inc. | Methods for identifying and isolating cells expressing a polypeptide |
JP5964249B2 (ja) | 2010-03-02 | 2016-08-03 | アッヴィ・インコーポレイテッド | 治療用dll4結合タンパク質 |
WO2012068098A1 (en) | 2010-11-15 | 2012-05-24 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer with dll4 antagonists |
CN106167526A (zh) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | Rspo结合剂和其应用 |
WO2013044215A1 (en) | 2011-09-23 | 2013-03-28 | Oncomed Pharmaceuticals, Inc. | Vegf/dll4 binding agents and uses thereof |
US9181333B2 (en) | 2012-07-13 | 2015-11-10 | Oncomed Pharmaceuticals, Inc. | RSPO3 binding agents and uses thereof |
WO2014071018A1 (en) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
-
2007
- 2007-09-28 MX MX2009003229A patent/MX2009003229A/es active IP Right Grant
- 2007-09-28 JP JP2009530419A patent/JP5535633B2/ja not_active Expired - Fee Related
- 2007-09-28 HU HUE07838966A patent/HUE028379T2/en unknown
- 2007-09-28 RS RS20160035A patent/RS54452B1/en unknown
- 2007-09-28 EA EA200970335A patent/EA018260B1/ru not_active IP Right Cessation
- 2007-09-28 NZ NZ576404A patent/NZ576404A/en unknown
- 2007-09-28 ME MEP-2016-8A patent/ME02371B/me unknown
- 2007-09-28 PL PL07838966T patent/PL2066694T3/pl unknown
- 2007-09-28 EP EP12185260A patent/EP2562188A3/en not_active Withdrawn
- 2007-09-28 CA CA2664738A patent/CA2664738C/en active Active
- 2007-09-28 ES ES07838966.5T patent/ES2557953T3/es active Active
- 2007-09-28 DK DK07838966.5T patent/DK2066694T3/en active
- 2007-09-28 WO PCT/US2007/020889 patent/WO2008042236A2/en active Application Filing
- 2007-09-28 PT PT78389665T patent/PT2066694E/pt unknown
- 2007-09-28 US US11/905,392 patent/US7750124B2/en active Active
- 2007-09-28 EP EP17205290.4A patent/EP3357932A1/en not_active Withdrawn
- 2007-09-28 EP EP07838966.5A patent/EP2066694B1/en active Active
- 2007-09-28 SI SI200731729T patent/SI2066694T1/sl unknown
- 2007-09-28 KR KR1020097008735A patent/KR101477824B1/ko not_active IP Right Cessation
- 2007-09-28 BR BRPI0717431-4A patent/BRPI0717431A2/pt not_active IP Right Cessation
- 2007-09-28 AU AU2007305443A patent/AU2007305443B2/en active Active
-
2009
- 2009-03-06 ZA ZA2009/01615A patent/ZA200901615B/en unknown
- 2009-03-18 CR CR10667A patent/CR10667A/es not_active Application Discontinuation
- 2009-03-19 IL IL197721A patent/IL197721A/en active IP Right Grant
- 2009-03-26 CO CO09031240A patent/CO6180466A2/es active IP Right Grant
- 2009-04-22 MA MA31810A patent/MA30808B1/fr unknown
- 2009-04-24 NO NO20091635A patent/NO20091635L/no not_active Application Discontinuation
-
2010
- 2010-01-27 HK HK10100861.4A patent/HK1133268A1/xx not_active IP Right Cessation
- 2010-05-18 US US12/782,429 patent/US9376497B2/en active Active
-
2013
- 2013-03-14 US US13/826,103 patent/US9228020B2/en active Active
-
2014
- 2014-03-06 JP JP2014043403A patent/JP5997194B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-21 CY CY20161100065T patent/CY1117154T1/el unknown
- 2016-01-26 HR HRP20160082TT patent/HRP20160082T1/hr unknown
- 2016-05-27 US US15/167,510 patent/US20160367667A1/en not_active Abandoned
- 2016-08-25 JP JP2016164264A patent/JP2017002076A/ja active Pending
-
2018
- 2018-08-24 US US16/111,841 patent/US20190060453A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160082T1 (hr) | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka | |
HRP20151261T1 (hr) | Sastavi i postupci za lijeäśenje i dijagnosticiranje raka | |
HRP20201595T1 (hr) | Anti-pd-l1 protutijela i njihova uporaba | |
JP2020152735A5 (hr) | ||
JP2019110906A5 (hr) | ||
HRP20190605T1 (hr) | Protutijela anti-fxi i postupci njihove uporabe | |
RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
AU2007324509B2 (en) | Novel antiproliferation antibodies | |
RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
RU2014143785A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака печени | |
HRP20130922T1 (hr) | U potpunosti humana protutijela protiv humanog 4-1bb (cd137) | |
HRP20221471T1 (hr) | Protutijela anti-fgfr3 i postupci za njihovu uporabu | |
HRP20150256T1 (hr) | Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe | |
HRP20110599T1 (hr) | Antitijela protiv toksina clostridium difficile i njihove primjene | |
HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
JP2014158469A5 (hr) | ||
CA2896058A1 (en) | Prolactin receptor binding proteins and uses thereof | |
JP2015500207A5 (hr) | ||
JP2010504755A5 (hr) | ||
KR20120089659A (ko) | 치료용 dll4 결합 단백질 | |
RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
JP2018535948A5 (hr) | ||
JP2024016024A5 (hr) | ||
JP2024026170A (ja) | 癌を処置するための組成物及び方法 | |
RU2016145277A (ru) | Антитело против igf-1r и его применение в качестве адресующего переносчика для лечения рака |